Erzotabart
- Generic Name
- Erzotabart
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Phase 1
Active, not recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)Diffuse Large B Cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Genmab
- Target Recruit Count
- 130
- Registration Number
- NCT04824794
- Locations
- 🇳🇿
North Shore Hospital, Takapuna, New Zealand
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath